What happened with VNDA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Vanda Pharmaceuticals Inc.’s revenue comes from Fanapt, used for schizophrenia and bipolar I disorder, and HETLIOZ, used for the sleep-wake disorder Non-24 and nighttime sleep disturbances associated with Smith-Magenis syndrome. Fanapt is its largest seller. PONVORY, for relapsing multiple sclerosis, contributes a smaller share. NEREUS is approved in the United States to prevent motion-induced vomiting, but its proposed use for gastroparesis remains unapproved.
The company’s direct customers are a small group of specialty pharmacies, specialty distributors and wholesalers, with a handful accounting for most revenue. Sales depend on government and private insurers covering prescriptions and on patients obtaining that coverage. These hurdles have limited HETLIOZ sales, while U.S. generic competition has also reduced its demand and price.
Vanda has no manufacturing facilities of its own and relies on outside companies to make and distribute its medicines. Patheon, part of Thermo Fisher Scientific, manufactures Fanapt tablets and HETLIOZ capsules. Maintaining supply depends on these contractors; replacing a manufacturer requires regulatory approval. Vanda’s ability to market its drugs is also limited to approved uses in each market.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Vanda’s results hinge on Fanapt growth and defending HETLIOZ sales against generics, including those from Apotex, which is absent from this list.
Teva sells generic HETLIOZ in the United States, putting Vanda’s branded capsule sales under pressure, and faces Vanda’s patent lawsuits. Watch news on those cases: Vanda warns that generic competition could cause further significant HETLIOZ sales declines.
Amneal sells MSN’s generic HETLIOZ in the United States, competing for sales with Vanda’s branded medicine. It is also a defendant in Vanda’s still-pending lawsuit over the product’s advertising and related representations, making that case another development to watch for HETLIOZ.
AbbVie’s Vraylar competes directly with Vanda’s Fanapt for patients with schizophrenia and bipolar I disorder, making Vraylar sales a rival to watch for Fanapt.
Johnson & Johnson sells its Invega antipsychotic medicines to schizophrenia patients who could also use Vanda’s Fanapt; Invega’s sales to that patient group are the overlap to watch.
Bristol Myers Squibb competes with two Vanda medicines: it sells Cobenfy for schizophrenia against Fanapt, and Zeposia for relapsing multiple sclerosis against PONVORY.
Novartis sells Kesimpta and Mayzent for multiple sclerosis, competing with Vanda’s PONVORY for relapsing-MS patients; those two medicines are the sales lines to watch rather than Novartis’s overall business.
Vanda depends on AnaptysBio’s exclusive global license to develop imsidolimab, while AnaptysBio earns license and transition-services revenue from Vanda and is eligible for sales royalties. Watch the revenue tied to this partnered medicine, rather than assuming AnaptysBio’s other royalty income reflects Vanda’s progress.
Vanda relies on Thermo Fisher’s Patheon subsidiaries to manufacture and package Fanapt tablets and HETLIOZ capsules, paying for production rather than running its own factories. Watch production interruptions or failed regulatory inspections at those facilities: replacing a manufacturer requires FDA approval and could delay Vanda’s supply and sales.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher’s report may reveal whether its Patheon manufacturing operations supporting Vanda’s Fanapt tablets and HETLIOZ capsules face disruption.
Watch for reported manufacturing interruptions or regulatory inspection problems at the relevant Patheon sites. Trouble there could delay the outside production Vanda needs for both products, putting supply and sales at risk; no reported trouble would reduce concern about this link, though it would not confirm Vanda’s available stock.
Novartis AG earningsNVS
Novartis’s report will show whether Kesimpta and Mayzent are still winning sales among relapsing-MS patients who are also potential PONVORY users.
Focus on sales for Kesimpta and Mayzent, not Novartis’s total revenue. Growth in those medicines would show competitors are drawing demand from the patient group PONVORY serves, keeping pressure on Vanda’s product; declines would soften that competitive signal, but would not establish that PONVORY sales rose.
ABBVIE INC. earningsABBV
AbbVie’s report will show whether Vraylar is still drawing sales from the schizophrenia and bipolar I patient groups that overlap with Vanda’s Fanapt.
Look for Vraylar sales and any indication-level detail AbbVie reports. Growing sales in the overlapping patient groups would show the rival remains a strong draw and could make Fanapt’s growth harder to sustain; weakening sales would lessen that competitive pressure, but only Vanda’s own report can show whether Fanapt is gaining ground.
Teva Pharmaceutical Industries Limited earningsTEVA
Teva’s report may show whether its generic HETLIOZ is gaining ground against Vanda’s branded capsules or disclose developments in their patent disputes.
Look for specific disclosure about generic HETLIOZ sales or the Vanda patent cases; Teva’s overall results do not answer either question. Stronger generic sales would point to more competition for Vanda’s branded capsules, while a case development favorable to Vanda could affect that competitive path. Little detail or no change would leave the effect on HETLIOZ sales unresolved.
Vanda Pharmaceuticals Inc. earningsThis company
Vanda’s report will show whether Fanapt sales can offset pressure on HETLIOZ and PONVORY while the company funds its drug programs.
Read sales by product alongside operating cash use. Fanapt sales holding or growing while HETLIOZ and PONVORY stabilize, with cash use easing, would show the leading product is supporting the portfolio with less funding strain. If Fanapt weakens as HETLIOZ keeps falling, especially with cash use rising, product concentration and development spending are putting greater pressure on Vanda’s ability to fund its plans.
